← All trials
NCT05675410
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2023
- Primary completion
- Apr 28, 2031
- Completion date
- Apr 28, 2031
- First posted
- Jan 9, 2023
- Last posted
- Dec 27, 2024
- Enrollment
- 1875
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- State University of New York, BuffaloOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.